Regression of glioblastoma after chimeric antigen receptor T-cell therapy

New England Journal of Medicine

Volumn 375, Issue 26, 2016, Pages 2561-2569

  Brown, Christine E ^a   Alizadeh, Darya ^a   Starr, Renate ^a   Weng, Lihong ^a   Wagner, Jamie R ^a   Naranjo, Araceli ^a   Ostberg, Julie R ^a   Blanchard, M Suzette ^b   Kilpatrick, Julie ^b   Simpson, Jennifer ^b   Kurien, Anita ^a   Priceman, Saul J ^a   Wang, Xiuli ^a   Harshbarger, Todd L ^b   D'Apuzzo, Massimo ^b   Ressler, Julie A ^b   Jensen, Michael C ^b,c   Barish, Michael E ^b   Chen, Mike ^b   Portnow, Jana ^b   Forman, Stephen J ^a   Badie, Behnam ^b   more..

^a Department of Hematology and Hematopoietic Cell Transplantation   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c Seattle Children's Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; CYTOKINE; INTERLEUKIN 13 RECEPTOR ALPHA2; T LYMPHOCYTE RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

ADVERSE DRUG REACTION; ARTICLE; BIOENGINEERING; BRAIN SURGERY; BRAIN VENTRICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER SIZE; CANCER SURGERY; CEREBROSPINAL FLUID; DISEASE ACTIVITY; DRUG EFFICACY; DRUG INFUSION; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; FATIGUE; GLIOBLASTOMA; HEADACHE; HUMAN; IMMUNOCOMPETENT CELL; MYALGIA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; ADOPTIVE IMMUNOTHERAPY; CASE REPORT; CD8+ T LYMPHOCYTE; CELL ENGINEERING; CLINICAL TRIAL; IMMUNOLOGY; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PHASE 1 CLINICAL TRIAL; TUMOR RECURRENCE;

CD8-POSITIVE T-LYMPHOCYTES; CELL ENGINEERING; COMBINED MODALITY THERAPY; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, ANTIGEN, T-CELL;

EID: 85007288271     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1610497     Document Type: Article

References (25)

1. Brown CE, Starr R, Aguilar B, et al. Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells. Clin Cancer Res 2012; 18: 2199-209.
2. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 2004; 64: 9160-6.
3. Debinski W, Gibo DM, Hulet SW, Connor JR, Gillespie GY. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res 1999; 5: 985-90.
4. Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014; 123: 2625-35.
5. Ramos CA, Savoldo B, Dotti G. CD19- CAR trials. Cancer J 2014; 20: 112-8.
6. Batlevi CL, Matsuki E, Brentjens RJ, Younes A. Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol 2016; 13: 25-40.
7. Kakarla S, Gottschalk S. CAR T cells for solid tumors: armed and ready to go? Cancer J 2014; 20: 151-5.
8. Priceman SJ, Forman SJ, Brown CE. Smart CARs engineered for cancer immunotherapy. Curr Opin Oncol 2015; 27: 466-74.
9. Brown CE, Badie B, Barish ME, et al. Bioactivity and safety of IL13Rα2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin Cancer Res 2015; 21: 4062-72.
10. Yaghoubi SS, Jensen MC, Satyamurthy N, et al. Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma. Nat Clin Pract Oncol 2009; 6: 53-8.
11. Jonnalagadda M, Mardiros A, Urak R, et al. Chimeric antigen receptors with mutated IgG4 Fc spacer avoid Fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther 2015; 23: 757-68.
12. Wang X, Berger C, Wong CW, Forman SJ, Riddell SR, Jensen MC. Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. Blood 2011; 117: 1888-98.
13. Wang X, Naranjo A, Brown CE, et al. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale. J Immunother 2012; 35: 689-701.
14. Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 2015; 314: 2535-43.
15. Debinski W, Thompson JP. Retargeting interleukin 13 for radioimmunodetection and radioimmunotherapy of human highgrade gliomas. Clin Cancer Res 1999; 5: Suppl: 3143s-3147s.
16. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010; 28: 1963-72.
17. Brentjens RJ, Rivière I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011; 118: 4817-28.
18. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26: 5233-9.
19. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014; 6: 224ra25.
20. Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J 2014; 20: 119-22.
21. Cerny C, Bronger H, Davoodi M, et al. The role of CXCR3/ligand axis in cancer. Int Trends Immun 2015; 3: 46-52 (http://research pub .org/ journal/ iti/ abstract/ vol3-no2 .html# paper3).
22. Liu M, Guo S, Stiles JK. The emerging role of CXCL10 in cancer (review). Oncol Lett 2011; 2: 583-9.
23. Maus MV, Haas AR, Beatty GL, et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res 2013; 1: 26-31.
24. Ahmed N, Brawley V, Hegde M, et al. Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a phase I trial. J Immunother Cancer 2015; 3(Suppl 2): O11 (http://jitc .biomedcentral .com/ articles/ 10 .1186/ 2051-1426-3-S2-O11).
25. O'Rourke DM, Nasrallah M, Morrissette JJ, et al. Pilot study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma. J Clin Oncol 2016; 34: 2067 (http://meeting library .asco .org/ content/ 171405-176).